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Objectives: The aim of this study was retrospectively to identify tumor characteristics or any other
prognostic factors that inﬂuence disease survival after curative rectal cancer resection.
Patients and Methods: The records of 95 patients with Stages I, II, or III rectal cancer (TNM system) seen
from August 2008 to June 2012 in one institution were reviewed. The patients underwent radical surgery
(abdominoperineal resection or laparoanterior resection with lymph node dissection) as deﬁnitive
therapy and then adjuvant treatment if pathology indicated T3 or T4 lesions, lymph node involvement, or
positive margins. Radiation therapy (54 Gy) was delivered to the gross tumor volume and 45e50 Gy to
the nodal region. The chemotherapy protocol consisted of 12 biweekly courses of oxaliplatin (85 mg/m2),
5-ﬂuorouracil (FU) (400 mg/m2), and leucovorin (400 mg/m2) on Day 1, followed by continuous infusion
of 5-FU (2400 mg/m2) for 48 hours.
Results: The 3-year cumulative overall survival rates for Stages I, II, and III rectal cancer were 100%, 100%,
and 75%, respectively. Univariate analysis for all 91 patients indicated that pN classiﬁcation, stage, sur-
gical margin  10 mm, and extracapsular spread (ECS) were signiﬁcantly associated with overall survival.
The pN classiﬁcation and stage also signiﬁcantly affected the disease-free survival and distant metastasis-
free survival. Furthermore, univariate analysis indicated vascular permeation, neural invasion, and sur-
gical margin  10 mmwere signiﬁcantly associated with disease-free survival. Vascular permeation also
signiﬁcantly affected distant metastasis-free survival. On multivariate analysis for all patients, pN clas-
siﬁcation and close surgical margin signiﬁcantly affected disease-free survival.
Conclusion: The presence of lymph node involvement and close margins was associated with lower
disease-free survival. More aggressive postoperative therapy is suggested for patients if these factors
exist.
Copyright  2013, Buddhist Compassion Relief Tzu Chi Foundation. Published by Elsevier Taiwan LLC. All
rights reserved.1. Introduction
Colorectal cancer is one of the most frequently diagnosed can-
cers and a major cause of cancer deaths worldwide. The incidence
of colorectal cancer is increasing and the condition remains thencology, Buddhist Dalin Tzu
Chiayi, Taiwan, Tel.: þ886
. Hung).
ddhist Compassion Relief Tzu Chimajor cause of death from cancer in Taiwan [1]. Rectal cancer has
a high rate of local relapse after surgery alone, with approximately
half of recurrences located in the pelvis [2]. The primary treatment
for rectal cancer is resection of the primary tumor, and adjuvant
treatment is needed in high-risk patients [3]. Adjuvant chemo-
therapy and radiation therapy have been shown to be effective
in reducing or eradicating cancers. In the late 1950s, ﬂuorouracil
(5-FU), administered in a bolus, was the chemotherapeutic agent of
choice in the management of advanced colorectal carcinoma.
Subsequently, 5-FU, of which prolonged exposure leads to
increased antitumor activity, was the treatment of choice [4]. Then,
postoperative chemoradiotherapy (CCRT) for Stage II and III rectalFoundation. Published by Elsevier Taiwan LLC. All rights reserved.
Table 1
Patient characteristics.
Variable No. of patients %
Age
<65 y 38 41.8
65 y 53 58.2
Sex
Male 50 54.9
Female 41 45.1
pT
1e2 25 27.5
3e4 66 72.5
pN
0 60 65.9
1e2 31 34.1
pStage
I 21 23.1
II 39 42.9
III 31 34.1
Extracapsular spread
Negative 79 86.8
Positive 12 13.2
Lymphatic permeation
Negative 37 40.7
Positive 54 59.3
Vascular permeation
Negative 80 87.9
Positive 11 12.1
Neural invasion
Negative 64 70.3
Positive 27 29.7
pN ¼ node metastasis; pStage ¼ pathologic stage; pT ¼ tumor extent.
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ability of many new chemotherapy and targeted therapy agents has
increased survival in patients with colorectal cancer [6]. Despite the
many new agents and modern techniques, local recurrence and
distant metastasis remain a challenge, especially in patients with
advanced stage disease. Therefore, the aim of this study was to
retrospectively determine tumor characteristics or any other
prognostic factors that inﬂuence survival after curative resection
for rectal cancer.
2. Patients and methods
The records of 95 patients with Stage I to III rectal cancer (TNM
system) seen fromAugust 2008 to June 2012 in one institutionwere
reviewed. These patients received radical surgery as deﬁnitive
therapy and then adjuvant CCRT if the pathology report indicated
T3 or T4 lesions, lymph node involvement, or positivemargins. Four
patients were excluded from the analysis because of loss to follow-
up (3 patients) or occurrence of a synchronous second primary
tumor (1 patient). In all patients, rectal cancer was diagnosed his-
tologically by pathologists and none of these patients had a history
of cancer. All patients were informed about their disease treatment,
including potential beneﬁts and possible adverse effects, and were
treated by multidisciplinary teams of colorectal surgeons, radiation
oncologists, medical oncologists, and dieticians.
2.1. Ethics statement
The study followed the Declaration of Helsinki guidelines. The
study protocol was approved by the Buddhist Dalin Tzu Chi General
Hospital Institutional Review Board (B10102003).
2.2. Treatment
Radical surgery consisted of abdominoperineal resection or
laparoanterior resection with lymph node dissection. Pathology
reports were reviewed to establish tumor size, grade, type, surgical
margins, lymph nodes involved, perineural invasion, vascular per-
meation, lymphatic permeation, and extracapsular spread (ECS).
Subclavian venous-access catheters were placed for nutritional
support and administration of chemotherapy. Adjuvant treatments
were started 4e6 weeks after surgery. Adjuvant CCRT plus che-
motherapy was indicated for T3 lesions, T4 lesions, lymph node
involvement, or positive margins.
Radiation therapy was delivered using three-dimensional con-
formal techniques. The radiation ﬁeld encompassed the primary
tumor bed and pelvic lymph nodes. Treatment was delivered with
a 6e10 MV multileaf collimator system (Precise, Elekta, Crawley,
UK) using a step-and-shoot method with ﬁve coplanar beams. The
critical normal structures used for optimization included the
bladder and rectum. The treatment plan and dose were veriﬁed
before treatment; a weekly machine-check ﬁlm involving elec-
tronic portal imaging was performed to ensure setup accuracy
during treatment. The prescribed doses delivered by external beam
radiation therapy were as follows: 50e54 Gy to the gross tumor
volume and 45e50 Gy to the nodal region. Conventional radiation
therapy fractionation was given, namely 1.8e2.0 Gy per day and 5
days per week for 6 weeks. Chemotherapy was given concurrently
with and after radiation therapy. The chemotherapy protocol con-
sisted of 12 biweekly courses of oxaliplatin (85 mg/m2), 5-FU
(400 mg/m2), and leucovorin (400 mg/m2) on Day 1, followed by
continuous infusion of 5-FU (2400 mg/m2) for 48 hours. Treatment
was withheld for Grade 3 and 4 toxicity according to the common
toxicity criteria of the National Cancer Institute, V2.0 [7].2.3. Patient follow-up and patterns of failure
Patients were assessed at 3, 6, and 12months and then every 6e
12 months for 5 years; this was done more often if clinically indi-
cated. Survival was calculated from the date of diagnosis to the date
of the most recent follow-up, recurrence, or death. The pattern of
failure was deﬁned according to the ﬁrst site of failure. Local failure
was deﬁned as recurrence of the primary tumor; locoregional fail-
ure, as recurrence of metastasis to the regional lymph nodes; and
distant failure, as metastasis to any site beyond the primary tumor
and the regional lymph nodes. After recurrence or metastasis, pa-
tients received salvage therapy as determined by their physicians.3. Statistical analysis
Baseline characteristics were analyzed using a t-test for con-
tinuous variables and a c2 test for categorical variables. The Kaplan-
Meier method was used for survival analysis [8]. The difference
between groups was determined using the log-rank test [9]. Cox
proportional hazard regression was used to perform multivariate
hazard ratio (HR) analysis. For estimating the effective size, HR was
provided with a 95% conﬁdence interval (CI) in addition to a con-
ventional p value. SPSS 12.0 software (SPSS Inc, Chicago, IL, USA)
was used for the analysis of all data. A statistically signiﬁcant dif-
ference was deﬁned by p < 0.05.4. Results
The patient characteristics are presented in Table 1. The mean
age was 65 years (range, 35e86 years). The median patient follow-
up at the commencement of the analysis was 18 months (range, 3e
38 months). Of the 21 patients with Stage I disease, 19 patients
received surgery alone and two received surgery plus single adju-
vant therapy. Of the 39 patients with Stage II disease, ﬁve received
surgery alone, 26 received surgery plus adjuvant CCRT, and eight
Table 3
Signiﬁcant prognostic factors associated with worse disease-free survival identiﬁed
by multivariate Cox regression analysis.
Factor HR (95% CI) p
Age, y 1.01 (0.91e1.10) 0.74
Sex 0.74 (0.07e8.30) 0.80
pN classiﬁcation 26.26 (1.52e453.47) 0.02*
Extracapsular spread 0.07 (0.00e3.13) 0.17
Lymphatic permeation 1.84 (0.09e36.40) 0.69
Vascular permeation 4.80 (0.28e83.41) 0.28
Neural invasion 4.24 (0.46e39.28) 0.20
Close surgical margins 21.14 (1.90e234.74) 0.01*
*Statistically signiﬁcant difference for multivariate analysis (p < 0.05).
CI ¼ conﬁdence interval; HR ¼ hazard ratio; pN ¼ node metastasis.
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with Stage III disease, six received surgery alone, 19 received sur-
gery plus adjuvant CCRT, and six received surgery plus single
adjuvant therapy. The radiotherapy dose was 2340e6120 cGy
(median, 5040 cGy). Of the 47 patients receiving radiotherapy, 35
received the full planned dose and 12 received an incomplete dose
because of treatment-induced complications. Forty-seven of the 59
patients who received chemotherapy completed the full course of
chemotherapy and the others received less than 12 cycles at
a reduced dose. The 3-year cumulative overall survival rates for
Stages I, II, and III were 100%, 100%, and 75%, respectively. The other
rates are summarized in Table 2.
Univariate analysis for all 91 patients indicated signiﬁcant as-
sociations of pN classiﬁcation, stage, surgical margin  10 mm, and
ECS with overall survival (Table 2). The pN classiﬁcation and stage
also signiﬁcantly affected disease-free survival and distant
metastasis-free survival. Furthermore, univariate analysis indicated
signiﬁcant associations of vascular permeation, neural invasion,
and surgical margin  10 mm with disease-free survival. Vascular
permeation also signiﬁcantly affected distant metastasis-free sur-
vival (Table 2). Multivariate analysis for all patients found no sig-
niﬁcant associations with overall survival. However, pN
classiﬁcation and close surgical margins signiﬁcantly affected
disease-free survival (Table 3) and were the two most signiﬁcant
factors affecting clinical outcome.5. Discussion
Patients with rectal cancer are at high risk for local and systemic
relapse, especially in the advanced stage [10]. In the current study,
pN classiﬁcation and close margins were the most importantTable 2
The 3-year clinical outcomes according to prognostic factors.
Risk factor 3-y overall
survival rate (%)
p 3-y disease-free
survival rate (%)
p
Age
<65 y 80.0 0.61 91.2 0.68
65 y 94.2 91.7
Sex
Male 87.2 0.37 93.1 0.90
Female 97.4 90.7
pT
1-2 100 0.22 100 0.12
3-4 89.3 88.5
pN
0 100 0.003* 98.3 0.00
1-2 75.0 77.2
pStage
I 100 0.013* 100 0.01
II 100 97.4
III 75.0 77.2
Extracapsular spread
Negative 93.8 0.019* 92.0 0.65
Positive 82.5 91.7
Lymphatic permeation
Negative 97.3 0.53 97.3 0.30
Positive 88.8 88.8
Vascular permeation
Negative 92.6 0.38 93.7 0.04
Positive 88.9 72.7
Neural invasion
Negative 93.5 0.21 96.3 0.03
Positive 92.3 79.6
Surgical margins
10 mm 79.7 0.046* 82.1 0.03
>10 mm 98.4 94.4
*Statistically signiﬁcant difference (p < 0.05)
pN ¼ node metastasis; pStage ¼ pathologic stage; pT ¼ tumor extent.outcome predictors in resectable rectal cancer. In addition, a high
rate of treatment failure, especially failure at distant sites, was
observed in patients with Stage III rectal cancer. Thus, in clinical
practice, it is reasonable to treat these patients aggressively.
The most important issue in postoperative treatment is accurate
staging, particularly nodal staging. Kim et al [11] reported poorer
overall survival in Stage N2 disease than in earlier stages. In addi-
tion, the number of involved lymph nodes has been positively
correlated with the number of examined lymph nodes [12].
Although there is still no consensus regarding the optimal number
of examined lymph nodes, many studies have reported that lymph
node ratio provides more useful information to guide adjuvant
treatment [13]. In the previous study, nodal status correlated with
treatment failure, particularly failure at distant sites. Although
treatment strategies for advanced disease have yet to be optimized,
more aggressive modalities such as combined targeted therapies
should be considered.3-y local free
rate (%)
p 3-y distant metastasis
-free rate (%)
p
96.3 0.24 91.2 0.94
100 93.5
97.1 0.35 94.9 0.59
100 90.7
100 0.53 100 0.15
97.8 89.9
5* 100 0.11 98.3 0.015*
94.4 79.8
9* 100 0.28 100 0.048*
100 97.4
94.4 79.8
98.3 0.77 93.1 0.48
100 91.7
100 0.49 100 0.09
97.7 88.8
7* 98.3 0.77 94.9 0.016*
100 72.7
* 97.9 0.56 96.3 0.09
100 82.6
5* 94.7 0.14 85.9 0.12
100 94.4
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However, the association with distal margins is not well estab-
lished. Nash et al. [14] reported increased risk of mucosal and
overall cancer recurrence in patients with close margins after
radical surgery. In addition, Komori et al. [15] demonstrated that
spread of different pathologic types can be discontinuous. The
average lengths of distal spread were 0.5  1.3 mm, 7.0  1.8 mm,
2.7  2.4 mm, and 10.0  9.5 mm for well-differentiated, mod-
erately differentiated, solid-type poorly differentiated, and
nonsolid-type poorly differentiated adenocarcinoma, respectively
[15]. Recently, Bernstein et al. [16] conﬁrmed that improved local
control of rectal cancer could reduce the risk of distant metastases.
Therefore, it is important to ensure an adequate surgical distal
resection margin. In our study, overall survival differed sig-
niﬁcantly between patients with surgical margin  10 mm and
patients with surgical margin >10 mm. In our population, primary
radical surgery was suggested for patients with surgical margin
>10 mm.
ECS, perineural invasion, and lymphatic vascular permeation
were common pathology ﬁndings in resected rectal cancer. ECS has
prognostic value in a variety of cancers, including prostate and head
and neck cancers [17,18]. However, only a few pathologic studies
have demonstrated a role for ECS in rectal carcinoma. Wind et al.
[19] identiﬁed ECS as an indicator of particularly aggressive
behavior and therefore its prognostic potential, especially in Stage
N2 disease. Another study also showed similar results, and that the
frequency of distant metastasis was increased in the presence of
ECS [20]. In our population, ECS was also an important factor
affecting survival. Similar to our report, other reports have identi-
ﬁed perineural invasion and lymphatic vascular permeation as
potential predictors. Chok et al [21] reported that lymphovascular
permeation and perineural invasion signiﬁcantly increased the risk
of lymph node metastasis and were predictive of poorer local
control or survival [21]. Importantly, Takahashi et al [22] provided
evidence of the beneﬁcial effects of adjuvant therapies in different
risk groups. Therefore, modern therapies such as targeted therapies
should be considered in the design of different strategies.
Because this is a retrospective study, factors relating to patients
and tumor characteristics could not be controlled for, and this may
have biased the results. However, the presence of lymph node
involvement and close margins were found to be strong prognostic
factors associated with disease-free survival. More aggressive
postoperative therapy is suggested for patients if these factors
exist.
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